The TFR-1 overexpression in malignant tumors has already been exploited in human medicine to internalize anticancer drugs more selectively and at a higher dosage in tumor cells by applying nanotechnology vectors, such as HFn [19,33]. Here, TFRC is linked to neoplasm.